Service d'Hématologie Pédiatrique, CHU Timone, Marseille, France.
AIDS. 2009 Nov 13;23(17):2364-6. doi: 10.1097/QAD.0b013e328331a456.
Twelve heavily pretreated, perinatally infected adolescents in virological failure were treated with a combination of raltegravir, r-darunavir and etravirine, as part of an expanded access program in France. After a 12-month median follow-up, viral load was <400 copies/ml in 11 (<50 in six). No grade > 2 side effects were recorded. Additional data and marketing authorizations are awaited, but preliminary results in adolescents with extensive multidrug resistant virus are encouraging.
12 名在病毒学上失败的重度预处理、围产期感染的青少年，作为法国扩大准入方案的一部分，接受了拉替拉韦、利托那韦和依曲韦林联合治疗。在中位 12 个月的随访后，11 名患者（6 名患者<50）的病毒载量<400 拷贝/ml。未记录到任何>2 级的不良反应。正在等待更多的数据和上市许可，但在广泛耐药病毒的青少年中，初步结果令人鼓舞。
